Last reviewed · How we verify
Vitamin D3 plus Dapagliflozin
Vitamin D3 acts as a hormone receptor agonist, while Dapagliflozin inhibits the SGLT2 transporter.
Vitamin D3 acts as a hormone receptor agonist, while Dapagliflozin inhibits the SGLT2 transporter. Used for Type 2 diabetes, Chronic kidney disease.
At a glance
| Generic name | Vitamin D3 plus Dapagliflozin |
|---|---|
| Sponsor | University Malaysia Sarawak |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Vitamin D3 binds to the vitamin D receptor (VDR), influencing gene expression and calcium homeostasis. Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting urinary glucose excretion.
Approved indications
- Type 2 diabetes
- Chronic kidney disease
Common side effects
- Increased risk of diabetic ketoacidosis
- Genital mycotic infections
- Increased risk of acute kidney injury
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin D3 plus Dapagliflozin CI brief — competitive landscape report
- Vitamin D3 plus Dapagliflozin updates RSS · CI watch RSS
- University Malaysia Sarawak portfolio CI